Table 2.

Cancers with an MSI-H frequency between 2% and 10%

Tumor type	Frequency, % (n)	Study
Ovarian	10% (1234)	Murphy and Wentzensen (82)
Cervical	8% (344)^a	Lazo (83)
Esophageal adenocarcinoma	7% (76)	Farris et al. (84)
Soft-tissue sarcoma	5% (40)	Kawaguchi et al. (85)
Head and neck SCC	3% (153)^b	Glavac et al. (86)
Renal cell carcinoma	2% (152)	Hammerschmied et al. (87)
Ewing sarcoma	2% (55)	Alldinger et al. (88)

Abbreviation: SCC, squamous cell carcinoma.

↵^aThis number represents an aggregate of studies with different definitions of MSI-H, not all of which meet the Bethesda guidelines.
↵^bMSI-H was defined as positivity in at least 2/8 markers.